Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy

NCT06588322 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT06588322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06588322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy
Lead sponsor
Institut Claudius Regaud
Phase
Not applicable
Overall status
Recruiting
Start date
January 8, 2025
Completion date
November 30, 2029
Enrollment
130 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer